PharmacoEconomics & Outcomes News 792, p6 - 2 Dec 2017 Bezlotoxumab cost effective for Clostridium difficile infection Bezlotoxumab appears to be cost effective for the prevention of recurrent Clostridium difficile infection (CDI), according to findings of a Merck & Co-funded study published in Clinical Infectious Diseases. A Markov model populated with data from the MODIFY I and II trials was used to evaluate the cost effectiveness of bezlotoxumab compared with placebo, in combination with standard of care (SoC) antibacterial therapy, in patients with a mild, moderate or severe episode of CDI. Cost effectiveness was assessed from a US third-party payer perspective over a lifetime time horizon in the overall MODIFY I/II trial population, and in subgroups who were elderly (≥65 years), immunocompromised, with severe CDI, and with one or more CDI episodes in the prior six months. In the total MODIFY population, bezlotoxumab was estimated to gain 0.12 QALYs compared with placebo at an incremental cost of $2444 per patient, resulting in an estimated incremental cost-effectiveness ratio (ICER) of $19 824 per QALY gained. Bezlotoxumab was also cost effective in subgroups of elderly patients, immunocompromised patients and patients with severe CDI, with ICERs of $15 298, $12 597 and $21 430 per QALY gained, respectively. Of note, bezlotoxumab was more cost effective in patients in these subgroups who had one or more previous episodes of CDI, with ICERs of $3591, $4979 and $2983 per QALY gained, respectively. The cost-effectiveness acceptability curve showed that there was 96.7% probability that bezlotoxumab was cost effective at a willingness-to-pay threshold of $50 000 per QALY gained. "Through prevention of recurrent CDI, bezlotoxumab administered together with SoC antibiotics is cost- effective compared with SoC alone," concluded the authors. "Given the urgent population-level threat of CDI identified by the US Centers for Disease Control and Prevention and the limited pharmacotherapy options available to prevent recurrent CDI, bezlotoxumab presents itself as a timely intervention to reduce the burden of recurrent CDI," they commented. * 2015 US dollars Prabhu VS, et al. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection. Clinical Infectious Diseases : 2 Nov 2017. Available from: URL: http://doi.org/10.1093/cid/ cix809 803284213 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera